Update 2021: Management of Small Cell Lung Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00408-021-00486-y.pdf
Reference62 articles.
1. Institute NC (2020) Cancer of the lung and bronchus (invasive). SEER database web site. https://seer.cancer.gov/csr/1975_2017/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.28. Accessed 12 Apr 2021
2. Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):725–737
3. Cardona AF, Rojas L, Zatarain-Barrón ZL et al (2019) Multigene mutation profiling and clinical characteristics of small-cell lung cancer in never-smokers vs. heavy smokers (Geno1.3-CLICaP). Front Oncol. https://doi.org/10.3389/fonc.2019.00254
4. Zhong J, Zheng Q, An T et al (2019) Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: a competing risk analysis. Thorac Cancer 10(9):1788–1797
5. Horn L, Mansfield AS, Szczęsna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities;Journal of Cancer Research and Clinical Oncology;2024-02-02
2. Histopathology images-based deep learning prediction of prognosis and therapeutic response in small cell lung cancer;npj Digital Medicine;2024-01-18
3. Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer;Frontiers in Oncology;2024-01-11
4. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress;Critical Reviews in Oncology/Hematology;2023-11
5. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response;Molecular Pharmaceutics;2023-10-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3